Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies

NCT01553071 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

16

Enrollment

NETWORK

Sponsor class

Stopped drug supply issues during COVID-19

Conditions

Solid Tumor

Interventions

DRUG: Fenretinide (4-HPR) plus Intravenous Safingol

Sponsor

South Plains Oncology Consortium